ACSS2 upregulation enhances neuronal resilience to aging and tau-associated neurodegeneration

N Naemeh Pourshafie (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) D Desi C. Alexander (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) H Hong Xu (Institute of Nuclear and New Energy Technology) K Kechun Yang (Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania) G Greg Donahue (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) X Xue Lei (Cancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute) S Shuo Zhang O Oksana Shcherbakova (Department of Biology, School of Arts and Sciences, University of Pennsylvania) C Connor Hogan (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) M Michael Gilbert (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) K Kevt’her Hoxha L Lesley Chaboub (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine) V Virginia M-Y Lee (Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine) P Peter D. Adams J John A. Dani (Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania) N Nancy M. Bonini (Department of Biology, School of Arts and Sciences, University of Pennsylvania) S Shelley L. Berger (Epigenetics Institute, University of Pennsylvania Perelman School of Medicine)

Abstract

Epigenetic mechanisms, including histone acetylation, regulate learning and memory and underlie Alzheimer’s disease and related dementia (ADRD). Acetyl-CoA synthetase 2 (ACSS2), an enzyme generating acetyl-CoA, locally regulates histone acetylation and gene expression in neuronal nuclei. This regulatory mechanism may be a promising target for therapeutic intervention in neurodegenerative diseases. Previously, we showed that systemic ACSS2 knockout mice, although largely normal in physiology, exhibit memory deficits. Here, we investigated whether increasing ACSS2 levels could protect neurons against disease and age-associated cognitive decline. Given the role of tau in ADRD, we used primary hippocampal neurons that mimic the sporadic development of tau pathology and the P301S transgenic mouse model for tau-induced memory decline. Our results show that ACSS2 upregulation mitigates tau-induced transcriptional alterations, enhances neuronal resilience against tau pathology, improves long-term potentiation, and ameliorates memory deficits. Additionally, boosting histone acetylation through ACSS2 countered age-related memory decline. These findings indicate that increasing ACSS2 is highly effective in countering age- and tau-induced transcriptome changes, preserving elevated levels of synaptic genes, and safeguarding synaptic integrity. These findings position ACSS2 as a key epigenetic regulator of cognitive aging and ADRD, highlighting its potential for targeted therapeutics to enhance brain resilience and function.

Article Details

Volume / Issue Vol. 123, Issue 2
Published January 13, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (17)

N

Naemeh Pourshafie

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

D

Desi C. Alexander

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

H

Hong Xu

Institute of Nuclear and New Energy Technology

K

Kechun Yang

Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania

G

Greg Donahue

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

X

Xue Lei

Cancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute

S

Shuo Zhang

O

Oksana Shcherbakova

Department of Biology, School of Arts and Sciences, University of Pennsylvania

C

Connor Hogan

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

M

Michael Gilbert

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

K

Kevt’her Hoxha

L

Lesley Chaboub

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine

V

Virginia M-Y Lee

Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine

P

Peter D. Adams

J

John A. Dani

Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania

N

Nancy M. Bonini

Department of Biology, School of Arts and Sciences, University of Pennsylvania

S

Shelley L. Berger

Epigenetics Institute, University of Pennsylvania Perelman School of Medicine